<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62171">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02025036</url>
  </required_header>
  <id_info>
    <org_study_id>FirstHenanUST</org_study_id>
    <nct_id>NCT02025036</nct_id>
  </id_info>
  <brief_title>The Effect of Capecitabine in the Radiotherapy of Esophageal Cancer</brief_title>
  <official_title>Two-arm Phase III Trial Comparing Radiotherapy With Different Chemotherapy Regimens for Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Henan University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Henan University of Science and Technology</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A two-arm Phase III trial was started in Jan 2014. Preoperative chemoradiotherapy with
      cisplatin plus 5-fluorouracil is the standard in Western countries in esophagus cancer. But
      in China because of its toxic reaction, most of patients stop the halfway.Preoperative
      chemotherapy with Capecitabine（Xeloda） plus oxaliplatin（ ELOXATIN） is another promising
      regimen. The purpose of this study is to confirm the difference of Capecitabine（Xeloda） plus
      oxaliplatin （ ELOXATIN）over Single drug Capecitabine（Xeloda） with chemoradiotherapy as
      preoperative therapy for squamous cell carcinoma of esophagus. A total of 300 patients will
      be accrued from Henan province in China within 3 years. The primary endpoint is overall
      survival and the secondary endpoints include progression-free survival, R0 resection rate,
      response rate, pathologic complete response rate and adverse events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We plan to recruit the patients who were pathologically confirmed with esophageal squamous
      cell carcinoma from the Jan 2014. The patients will be divided into two groups.Experimental
      group: single drug Capecitabine（Xeloda）and concurrent radiotherapy.Control group:with
      Capecitabine（Xeloda） plus oxaliplatin（ Eloxatin）and and concurrent radiotherapy. To evaluate
      the overall survival of the two group.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>overall survival, OS</measure>
    <time_frame>5years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>5years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall remission rate, ORR</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serious adverse event</measure>
    <time_frame>1month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life, Qol</measure>
    <time_frame>1month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pathologic complete response rate</measure>
    <time_frame>1month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>1month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2</enrollment>
  <condition>Stage III Esophageal Squamous Cell Carcinoma</condition>
  <condition>Stage II Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>XELOX and radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oxaliplatin（Eloxatin ）：85mg/m2，d1，15，29,I.V.plus,capecitabine（Xeloda）: 625mg/m2, bid d1-5; q1w, po,5 weeks in total, radiotherapy： 50Gy ，2 Gy/d，5d/w.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>capecitabine and radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>capecitabine（Xeloda）: 625-825mg/m2, bid d1-5 or d1-7，po,5 weeks, radiotherapy： 50Gy，2 Gy/d，5d/w.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin（Eloxatin ）</intervention_name>
    <description>oxaliplatin（Eloxatin ）：85mg/m2，d1，15，29 intravenous infusion,5 weeks in total</description>
    <arm_group_label>XELOX and radiotherapy</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine（Xeloda）</intervention_name>
    <description>capecitabine（Xeloda）: 625mg/m2, bid d1-5; q1w, po,5 weeks in total</description>
    <arm_group_label>XELOX and radiotherapy</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine（Xeloda）</intervention_name>
    <description>625-825mg/m2, bid d1-5 or d1-7，po,5 weeks in total</description>
    <arm_group_label>capecitabine and radiotherapy</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity</description>
    <arm_group_label>XELOX and radiotherapy</arm_group_label>
    <arm_group_label>capecitabine and radiotherapy</arm_group_label>
    <other_name>Radiation Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-75years old

          -  Histologically proven squamous cell carcinoma of the esophagus

          -  the tumor was in T2-4N0-1M0

          -  The patients have not received the surgery or chemo-radiotherapy.

          -  Hb≥80g/L, absolute neutrophil count  ≥1.5×109/L, Plt≥90×109/L,

          -  ALT、AST≤2.5*N,Cr≤1.5*N.

          -  performance status score 0-2

        Exclusion Criteria:

          -  pregnant, lactating women

          -  Oxaliplatin or fluorouracil Allergy or metabolic disorders

          -  Radiotherapy contraindications

          -  History of organ transplantation

          -  Brain metastasis

          -  The peripheral nervous system disorders

          -  Severe infection

          -  Oral capecitabine who have difficulty with,such as  dysphagia,The activities of
             digestive ulcer, Gastrointestinal bleeding

          -  Severe chronic diseases, such as, hepatopathy, nephropathy, respiratory disease,high
             blood pressure, diabetes.

          -  Other malignant tumor in recent 5 years.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>shegan gao, doctor</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>tanyou shan, Master</last_name>
    <role>Study Director</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>xiaoshan feng, doctor</last_name>
    <role>Study Director</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>jiachun sun, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>guoqiang kong, master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>xiaozhi yuan, master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ruinuo jia, master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>dan zhuo, master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>jing ren, master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>xinshuai wang, docter</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Henan University of Science and Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>shegan gao, doctor</last_name>
    <phone>18638859977</phone>
    <email>gsg112258@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>tanyou shan, master</last_name>
    <phone>13523623814</phone>
    <email>shantanyou@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Henan University of Science and Technology</name>
      <address>
        <city>Luoyang</city>
        <state>Henan</state>
        <zip>471003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Park JW, Kim JH, Choi EK, Lee SW, Yoon SM, Song SY, Lee YS, Kim SB, Park SI, Ahn SD. Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):691-7. doi: 10.1016/j.ijrobp.2010.06.041. Epub 2010 Oct 1.</citation>
    <PMID>20888705</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 30, 2013</lastchanged_date>
  <firstreceived_date>November 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
